4SC Achieves Next Milestone in Drug Discovery Collaboration with Sanwa Kagaku Kenkyusho
Under the terms of the agreement 4SC AG applied its proprietary virtual High Throughput Screening technology, 4Scan®, followed by biological screening experiments to identify active agents against specific targets provided by SKK.
In a second step 4SC AG optimised these hits chemically with respect to certain properties like potency, selectivity and their in vitro ADMET profile.
The completion of this research programme triggers another significant payment from SKK.
SKK is now responsible for further R&D. 4SC AG continues to participate in future potential milestone and royalty payments.
"We are very impressed by the quality of services and the remarkably short time frame 4SC AG needed to deliver promising leads during our collaboration," said Satoshi Terao, SKK's Vice President for Research and Development.
"Therefore we are optimistic, that we will work with 4SC AG again on similar projects."
"We are proud that we were able to exceed all expectations regarding the milestone criteria. This again is a proof of the value added by our technology and competence," said Ulrich Dauer, CEO of 4SC AG.